ANDA 209672, held by Cipla. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 209672 (Valganciclovir Hydrochloride), held by Cipla, was first approved by FDA on Nov 9, 2018, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 9, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir HydrochlorideEQ 450MG BASE · tablet;oral | Valganciclovir Hydrochloride | Discontinued |
| Jun 6, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 6, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 9, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters